Annovis Bio Inc
ANVS
Company Profile
Business description
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Contact
101 Lindenwood Drive
Suite 225
MalvernPA19355
USAT: +1 484 875-3192
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
AI stocks post big gains in Q3. These are the winners and losers
Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks
12 picks for an income portfolio - Q3 2025 update
Fifteen months in and passive income growth has exceeded my target.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,252.10 | 27.20 | -0.29% |
| CAC 40 | 7,971.78 | 109.76 | -1.36% |
| DAX 40 | 24,378.29 | 0.51 | -0.00% |
| Dow JONES (US) | 46,694.97 | 63.31 | -0.14% |
| FTSE 100 | 9,479.14 | 12.11 | -0.13% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,941.67 | 161.16 | 0.71% |
| Nikkei 225 | 48,247.17 | 302.41 | 0.63% |
| NZX 50 Index | 13,531.29 | 42.05 | 0.31% |
| S&P 500 | 6,740.28 | 24.49 | 0.36% |
| S&P/ASX 200 | 8,954.60 | 21.30 | -0.24% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |